Compare Heron Therapeutics Inc (HRTX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Skyworks Solutions Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Skyworks Solutions Inc trades at $61.46 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 98.3× Heron Therapeutics Inc's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SWKS | |
|---|---|---|
Market Cap | $91.46M | $8.99B |
Sector | Health | Technology |
52-Week High | $1.96 | $83.40 |
52-Week Low | $0.39 | $52.50 |
Enterprise Value | $189.36M | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Skyworks Solutions (SWKS) trades at $59.83, up 0.88% on the day, with a bearish technical signal but strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue has declined from $5.5B in 2022 to $4.1B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in AI and EV sectors and an ongoing legal investigation.
The outlook is mixed: analyst consensus is bullish with a $75.88 price target (58.34% buy ratings), but technicals and declining revenue pose risks. Key opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal scrutiny. The stock offers a dividend yield above 4%, supported by cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
